Are androgen receptor variants a substitute for the full-length receptor?

Ji Lu, Travis Van Der Steen, Donald J. Tindall

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations


Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalNature Reviews Urology
Issue number3
StatePublished - Mar 11 2015

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Are androgen receptor variants a substitute for the full-length receptor?'. Together they form a unique fingerprint.

Cite this